China Leads 1Q Emerging Markets Charge For AstraZeneca
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca's emerging markets business logged solid growth in the calendar first quarter, driven largely by big increases for its respiratory franchise in China, where the firm also sees a growing role for tiered pricing in oncology.